Sugi Predict

Sugi Predict / Compounds / SCHEMBL317506

SCHEMBL317506

SCHEMBL317506

Cc1ccc2c(Cl)ccnc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 4/20 0.54
▸ ADRA1D P25100 4/20 0.54
▸ ADRA1A P35348 4/20 0.54
▸ ADRA1B P35368 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.46
▸ CHEK1 O14757 1/20 0.44
▸ PARP1 P09874 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ RPS6KA3 P51812 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ NR4A2 P43354 2/20 0.43
▸ SOS2 Q07890 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TLR8 Q9NR97 1/20 0.42
▸ UHRF1 Q96T88 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30380536 1.00 HTR1A (0.54) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL25404944 0.85 MAPKAPK2 (0.45) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL4758609 0.84 LMNA (0.56) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL317202 0.79 NR4A2 (0.66) NR4A2SOS2MEN1MAPTKMT2A
SCHEMBL29396540 0.79 NR4A2 (0.66) NR4A2SOS2MEN1MAPTKMT2A
SCHEMBL873159 0.79 HTR1A (0.58) HTR1AADRA1DADRA1AADRA1BALDH1A1
Hydrochloric Acid SCHEMBL11519956 0.78 NR4A2 (0.63) NR4A2SOS2MEN1MAPTKMT2A
Bromide SCHEMBL1611919 0.78 NR4A2 (0.63) NR4A2SOS2MEN1MAPTKMT2A
Bromide SCHEMBL1611915 0.78 NR4A2 (0.63) NR4A2SOS2MEN1MAPTKMT2A
SCHEMBL6002911 0.78 TLR8 (0.43) HTR1AADRA1DADRA1AADRA1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 — — US disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-11751475-B2 Organic compound, display panel and display apparatus XIAMEN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) 2023-09-05 — — US disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2003101981-A1 NOVEL SUBSTITUTED INDOLES ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
US-6440995-B1 NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS HOFFMAN-LA ROCHE INC. 2002-08-27 — — US disclosed
US-6339093-B1 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. 2002-01-15 — — US disclosed
EP-1090917-A1 Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers F. HOFFMANN-LA ROCHE AG (CH) 2001-04-11 — — EP disclosed
CN-1290698-A Quinoline-4-base deviative I HOFFMANN LA ROCHE (CH) 2001-04-11 — — CN disclosed
EP-1088818-A1 Quinolin-4-yl derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-04-04 — — EP disclosed
US-5773449-A BACTERICIDES FOR HELICOBACTER ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 1998-06-30 — — US disclosed
EP-0786454-A1 THIOQUINOLONE DERIVATIVE ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 1997-07-30 — — EP disclosed
US-4057633-A ANTIANXIETY, HYPOTENSIVE THE UPJOHN COMPANY (US) 1977-11-08 — — US disclosed
US-3992382-A HYPERTENSION AND ANXIETY TREATMENT THE UPJOHN COMPANY (US) 1976-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR HTR1A 3633/4885ADRA1D 3965/4885ADRA1A 3465/4885
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 HTR1A 896/4885ADRA1D 987/4885ADRA1A 635/4885
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 HTR1A 813/4885ADRA1D 957/4885ADRA1A 779/4885
US-11751475-B2 Organic compound, display panel and display apparatus C3AR1, NR0B2, NR0B1 HTR1A 1004/4885ADRA1D 410/4885ADRA1A 1214/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 HTR1A 517/4885ADRA1D 225/4885ADRA1A 189/4885
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 HTR1A 380/4885ADRA1D 456/4885ADRA1A 439/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 HTR1A 813/4885ADRA1D 957/4885ADRA1A 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.